BioLight Life Sciences Research - aVenture Research
BioLight Life Sciences
BioLight Life Sciences is an Israeli company that invests solely in ophthalmology.
4
Public company
1Growth Drivers
BioLight prefers portfolio companies that sit relatively close to the revenue stage, a stance consistent with a portfolio approach aimed at commercial milestones; whether that approach lifts growth depends on holdings moving from early rollout toward revenue. Peripherex has an FDA-cleared product that has begun early rollout in clinics.
BioLight's 2025 revenue was zero, and its operating cash outflow was NIS 10.854 million.
2Market Outlook
Forecast expansion in ophthalmology drugs and devices favors BioLight Life Sciences' category exposure, with Mordor Intelligence estimating the market at USD 97.27 billion in 2026 and projecting USD 127.55 billion by 2031 at a 5.57% CAGR, while several of its ophthalmic products remain at mixed commercialization, clinical, and pre-clinical stages.
In 2024, Regeneron's EYLEA HD launched in the U.S. with 16-week dosing that halves intravitreal visits.
3Memo
BioLight Life Sciences can use its September 2025 public raise to advance its portfolio through the 2026 proof period, provided the 2026 milestones become financing, licensing, partnership or commercialization events; if they do not, the discussion moves back toward dilution.
Peripherex possesses an FDA-cleared product that has begun its early rollout across clinics.
4Risk Factors
BioLight's principal risk is that its 2026 portfolio milestones fail to produce financing, licensing, partnership or commercialization events before continued cash needs move the discussion back toward dilution.
BioLight's 2025 revenue was zero, and operating cash outflow was NIS 10.854 million.